ArticleBritish journal of cancer2015
Long-term adverse outcomes in survivors of childhood bone sarcoma: the British Childhood Cancer Survivor Study.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The Roles of TNF Signaling Pathways in Metabolism of Bone Tumors.Frontiers in pharmacology · 2022Pooled it
- Article
- Review
- Subsequent Primary Neoplasms and Mortality Among Survivors of Childhood Cancer in Alberta, Canada.Cancers · 2026Article
- Post-treatment late and long-term effects in bone sarcoma: A scoping review.Journal of bone oncology · 2025Review
- UK guidelines for the management of bone sarcomas.British journal of cancer · 2025Review
- Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma.Molecular cancer therapeutics · 2024Article
- Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century.Nature reviews. Clinical oncology · 2023Review
- Alberta Childhood Cancer Survivorship Research Program.Cancers · 2023Article
- Early postoperative gain in activity levels of lower extremity sarcoma survivors positively affects long-term physical activity and performance.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Family cancer history and smoking habit associated with sarcoma in a Japanese population study.Scientific reports · 2022Article
- Somatic Disease in Survivors of Childhood Malignant Bone Tumors in the Nordic Countries.Cancers · 2021Article
- Review
- Healthcare provider perspectives on pediatric cancer survivorship care plans: a single institution pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Cumulative Burden of Chronic Health Conditions in Adult Survivors of Osteosarcoma and Ewing Sarcoma: A Report from the St. Jude Lifetime Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Osteosarcoma and second malignant neoplasms: a case series.Irish journal of medical science · 2019Article
- Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.Cancer research · 2019Article
- Review of risk factors of secondary cancers among cancer survivors.The British journal of radiology · 2019Review
- Review
- Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.Pediatric blood & cancer · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWith improved survival, more bone sarcoma survivors are approaching middle age making it crucial to investigate the late effects of their cancer and its treatment. We investigated the long-term risks of adverse outcomes among 5-year bone sarcoma survivors within the British Childhood Cancer Survivor Study.
methodsCause-specific mortality and risk of subsequent primary neoplasms (SPNs) were investigated for 664 bone sarcoma survivors. Use of health services, health and marital status, alcohol and smoking habits, and educational qualifications were investigated for survivors who completed a questionnaire.
resultsSurvivors were seven times more likely to experience all-cause mortality than expected, and there were substantial differences in risk depending on tumour type. Beyond 25 years follow-up the risk of dying from all-causes was comparable to the general population. This is in contrast to dying before 25 years where the risk was 12.7-fold that expected. Survivors were also four times more likely to develop a SPN than expected, where the excess was restricted to 5-24 years post diagnosis. Increased health-care usage and poor health status were also found. Nonetheless, for some psychosocial outcomes survivors were better off than expected.
conclusionsUp to 25 years after 5-year survival, bone sarcoma survivors are at substantial risk of death and SPNs, but this is greatly reduced thereafter. As 95% of all excess deaths before 25 years follow-up were due to recurrences and SPNs, increased monitoring of survivors could prevent mortality. Furthermore, bone and breast SPNs should be a particular concern. Since there are variations in the magnitude of excess risk depending on the specific adverse outcome under investigation and whether the survivors were initially diagnosed with osteosarcoma or Ewing sarcoma, risks need to be assessed in relation to these factors. These findings should provide useful evidence for risk stratification and updating clinical follow-up guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.